gene
therapi
transfer
gene
patient
cell
therapeut
purpos
fig
gene
therapi
origin
envis
cure
inherit
monogenet
diseas
gene
correct
ie
replac
complement
caus
mutat
gene
function
copi
recent
decad
howev
gene
therapi
intens
investig
treatment
mani
diseas
transfer
divers
class
therapeut
gene
variou
speci
tabl
exampl
gene
encod
pathogen
antigen
prevent
treatment
infecti
diseas
genet
vaccin
gene
encod
agonist
antagonist
vascular
growth
factor
treatment
cardiovascular
diseas
gene
directli
indirectli
mediat
tumor
cell
kill
cancer
treatment
gene
therapi
drug
consist
therapeut
gene
defin
mode
therapeut
action
gene
transfer
vector
need
facilit
appropri
stabil
deliveri
express
therapeut
gene
fig
inde
major
effort
gene
therapi
research
focu
vector
develop
sinc
deliveri
therapeut
gene
complex
critic
determin
treatment
efficaci
sinc
multitud
gene
therapi
clinic
trial
perform
thousand
patient
therapeut
efficaci
demonstr
recent
exampl
restor
immun
scid
patient
restor
degre
vision
childhood
blind
inhibit
neurodegener
kohn
roy
et
al
cartier
et
al
howev
gene
therapi
approach
necessit
improv
efficaci
select
gene
transfer
order
facilit
success
applic
patient
ensur
proper
express
therapeut
gene
patient
cell
gene
therapi
vector
contain
promot
transcript
terminationpolyadenyl
signal
fig
regulatori
element
exploit
exampl
achiev
enhanc
intron
bicistron
intern
ribosom
entri
site
ire
gene
express
importantli
regulatori
element
exploit
spatial
tempor
control
gene
express
exampl
induc
cell
typespecif
promot
sequenc
differenti
regul
mrna
stabil
translat
effici
goverdhana
et
al
dorer
nettelbeck
brown
naldini
improv
stabil
therapeut
dna
eukaryot
express
cassett
insert
either
circular
plasmid
might
packag
nonvir
vector
genom
replicationdefici
viral
vector
tabl
deliveri
result
gene
drug
achiev
physic
method
exampl
plasmid
deliveri
skin
gene
gun
genet
vaccin
altern
deliveri
mediat
vector
exampl
penetr
viru
vector
target
tissu
uptak
cell
transfer
recombin
viru
genom
contain
therapeut
gene
nucleu
viral
transduct
ensur
safeti
virus
use
gene
transfer
vector
crippl
gene
delet
order
prevent
viru
replic
gene
transfer
vector
determin
fate
therapeut
gene
retrovir
vector
insert
genom
thu
therapeut
gene
host
cell
chromosom
wherea
plasmid
adenovir
vector
result
episom
gene
transfer
thu
retrovirus
facilit
stabl
gene
transfer
transduc
cell
progeni
requir
correct
treatment
inherit
diseas
exampl
ex
vivo
gene
transfer
hematopoiet
stem
cell
treatment
inherit
immunodefici
kohn
contrast
transient
gene
transfer
usual
suffici
genet
vaccin
cytoabl
cancer
therapi
latter
howev
effici
gene
transfer
pivot
thu
vector
choic
determin
transduct
effici
regard
condit
replicationcompet
viral
vector
recent
engin
allow
vector
spread
tumor
thu
amplifi
gene
transfer
parato
et
al
codi
dougla
replicationcompet
vector
also
mediat
tumor
cell
lysi
viru
replic
term
oncolysi
virotherapi
henc
perspect
virotherapist
insert
therapeut
gene
genom
oncolyt
virus
strategi
complement
oncolysi
gene
therapi
arm
oncolyt
virus
mani
gene
therapi
applic
requir
restrict
gene
transfer
specif
cell
obviou
cytoabl
gene
therapi
replicationcompet
vector
also
effect
genet
vaccin
depend
gene
transfer
appropri
immun
cell
antigen
express
wrong
cell
trigger
toler
rather
immun
consequ
vector
target
major
challeng
gene
therapi
research
target
gene
therapi
viral
replic
achiev
insert
cellbind
ligand
gene
transfer
vector
target
cell
entri
postentri
regul
therapeut
gene
express
use
appropri
regulatori
sequenc
mention
bispecif
antibodi
gene
therapi
connect
two
way
first
bispecif
antibodi
develop
promis
tool
target
cell
entri
gene
transfer
vector
adapt
molecul
link
vector
marker
molecul
specif
express
target
cell
surfac
fig
second
gene
therapi
altern
mean
deliveri
therapeut
antibodi
patient
ie
antibodi
product
patient
cell
genet
antibodi
therapi
fig
besid
genet
deliveri
establish
solubl
antibodi
antibodi
gene
transfer
also
facilit
new
applic
bispecif
antibodi
therapi
exampl
express
membranebound
intracellular
deriv
certainli
combin
therapi
bispecif
antibodi
gene
therapi
also
envis
bispecif
antibodi
exploit
gene
therapi
tool
direct
viral
gene
transfer
vector
diseas
cell
therefor
antibodi
specif
viral
surfac
protein
link
second
antibodi
bind
cell
surfac
molecul
interest
thu
implement
adapt
molecul
bind
gene
transfer
vector
target
cell
fig
modif
viru
tropism
requir
viru
receptor
express
lack
target
cell
prevent
gene
transfer
widespread
express
nativ
viru
receptor
healthi
cell
lead
advers
side
effect
vector
sequestr
latter
either
viral
attach
protein
mutat
without
lose
affin
adapt
receptorbind
domain
viru
attach
protein
shield
adapt
result
loss
viru
tropism
healthi
cell
term
detarget
bind
entri
target
cell
case
mediat
target
cellbind
moieti
adapt
retarget
import
advantag
adapt
strategi
requir
modif
viru
structur
might
well
turn
detriment
vector
assembl
stabil
activ
b
flexibl
vector
bind
target
molecul
antibodi
rais
possibl
exchang
adapt
cellbind
moieti
c
effect
adapt
specif
vector
gener
use
transfer
therapeut
gene
correspond
deriv
vector
bispecif
antibodi
adapt
target
gene
transfer
intens
investig
adenovir
vector
adenovirus
ad
mcconnel
imperial
possess
doublestrand
linear
dna
genom
cover
protein
capsid
lipid
envelop
receptorbind
spike
adenovir
capsid
made
trimer
fiber
protein
respons
attach
host
cell
bind
viru
receptor
coxsackieadenoviru
receptor
car
mostli
use
human
ad
serotyp
viru
intern
host
cell
mediat
secondari
interact
differ
viru
capsid
protein
penton
base
cellular
integrin
separ
cell
bind
entri
twostep
mechan
facilit
high
degre
flexibl
natur
initi
attach
ad
vector
cell
entri
vector
cell
viru
genom
transfer
nucleu
viral
gene
express
episom
genom
likewis
therapeut
gene
express
transfer
ad
vector
genom
patient
cell
therefor
essenti
viral
gene
replac
therapeut
gene
render
vector
replicationdefici
recent
therapeut
gene
insert
replicationcompet
ad
mcconnel
imperial
ad
repres
promin
gene
therapi
vector
stabl
produc
high
titer
possess
effect
gene
transfer
machineri
mildli
pathogen
caus
common
cold
symptom
mcconnel
imperial
frequent
use
viral
vector
clinic
gene
therapi
trial
journal
gene
medicin
clinic
trial
databas
trial
reveal
favor
safeti
profil
ad
vector
patient
cancer
gene
therapi
genet
vaccin
regimen
ad
vector
wide
use
one
therapeut
approach
cancer
gene
therapi
molecular
chemotherapi
also
term
genedepend
enzym
prodrug
therapi
gdept
strategi
base
transfer
gene
encod
prodrugactiv
enzym
activ
harmless
prodrug
effect
chemotherapeut
drug
portsmouth
et
al
rational
strategi
tumorrestrict
prodrug
activ
facilit
effect
concentr
chemotherapeut
drug
tumor
achiev
convent
system
infus
drug
due
doselimit
side
effect
gdept
cytoabl
cancer
gene
therapi
depend
tumorselect
gene
transfer
provid
unmodifi
ad
serotyp
due
widespread
express
ad
receptor
also
healthi
cell
ad
also
frequent
use
vector
genet
vaccin
effici
antigen
gene
transduc
profession
antigenpres
cell
apc
provid
proper
signal
activ
immun
effector
cell
dendrit
cell
dc
effect
apc
difficult
transduc
though
ad
effect
gene
transfer
vector
dc
high
vector
titer
requir
effici
dc
transduct
low
express
car
antibodi
attract
bind
molecul
target
gene
transfer
vector
base
high
affin
specif
opportun
gener
antibodi
specif
virtual
cell
surfac
target
molecul
three
strategi
pursu
insert
target
ligand
viral
gene
transfer
vector
genet
fusion
viral
capsid
envelop
protein
complex
bispecif
adapt
chemic
linkag
major
drawback
genet
chemic
strategi
tediou
often
interfer
viral
function
moreov
genet
insert
antibodi
adenovir
capsid
hamper
incompat
biosynthesi
capsid
antibodi
molecul
ad
capsid
protein
synthes
cytosol
transfer
nucleu
viral
particl
assembl
take
place
wherea
antibodi
produc
via
secretori
pathway
ensur
proper
fold
consequ
genet
fusion
antibodi
ad
capsid
protein
ineffici
limit
cytosol
stabl
antibodi
fragment
hedley
et
al
vellinga
et
al
poulin
et
al
contrast
synthesi
adapt
molecul
separ
viru
product
moreov
insert
cellbind
antibodi
adapt
molecul
less
tediou
engin
complet
new
viru
genom
result
adapt
link
ad
vector
allow
better
flexibl
product
adapt
antibodi
fragment
bind
ad
capsid
protein
mostli
fiber
antibodi
antibodi
fragment
bind
cell
surfac
target
molecul
interest
use
fig
link
chemic
conjug
see
also
genet
fusion
latter
gener
tandem
scfv
scdb
see
also
altern
bispecif
antibodi
adapt
gener
link
virusbind
antibodi
fragment
cellbind
protein
peptid
link
cellbind
antibodi
fragment
solubl
adenoviru
receptor
car
adapt
strategi
target
cell
entri
ad
vector
pioneer
dougla
cowork
target
folat
receptor
overexpress
tumor
cell
dougla
et
al
end
chemic
conjug
folat
fab
fragment
neutral
antiad
fiber
monoclon
antibodi
mab
fab
fragment
use
avoid
agglutin
ad
vector
bival
antibodi
complex
respect
ad
vector
adapt
mediat
folatedepend
transfer
report
gene
cytoabl
genet
prodrug
activ
target
cell
fab
fragment
alon
inhibit
adenovir
transduct
expect
deriv
neutral
antibodi
thu
fabfol
adapt
realiz
target
gene
transfer
ablat
viru
bind
nativ
viru
receptor
direct
viru
attach
novel
cell
surfac
molecul
fig
wickham
et
al
describ
bispecif
antibodi
direct
ad
cell
bind
integrin
adapt
consist
integrinbind
mab
chemic
link
second
mab
specif
peptid
tag
engin
ad
penton
base
wickham
et
al
conjug
mediat
enhanc
adenovir
transduct
human
smooth
muscl
endotheli
cell
modestli
tranduc
unmodifi
vector
subsequ
variou
bispecif
antibodi
conjug
report
consist
fiberbind
fab
fragment
coval
link
cellbind
antibodi
antibodi
fragment
bispecif
antibodi
conjug
report
redirect
ad
gene
transfer
variou
cell
type
via
bind
differ
cell
surfac
molecul
includ
epcam
ace
tillman
et
al
de
gruijl
et
al
brandao
et
al
miller
et
al
haisma
et
al
israel
et
al
reynold
et
al
report
confirm
high
flexibl
adapt
approach
exampl
dc
profession
antigenpres
cell
repres
target
interest
gene
transfer
aim
genet
vaccin
infecti
malign
diseas
conjug
fab
mab
bind
dc
surfac
molecul
allow
effici
ad
gene
transfer
mous
human
dc
tillman
et
al
adapt
improv
effici
select
ad
gene
transfer
dc
also
achiev
situ
use
human
skin
explant
de
gruijl
et
al
addit
target
ad
entri
mab
adapt
trigger
dc
activ
requir
effici
induct
immun
respons
via
activ
accordingli
adapt
increas
effici
tumor
vaccin
ad
vector
transduc
dc
anim
model
tillman
et
al
adapt
target
ad
vector
cancer
cell
demonstr
cell
cultur
studi
egfrbind
fabmab
conjug
squamou
cell
carcinoma
glioblastoma
osteosarcoma
miller
et
al
blackwel
et
al
barnett
et
al
epcambind
fabfab
conjug
variou
adenocarcinoma
haisma
et
al
heideman
et
al
fabmab
conjug
ovarian
cancer
kelli
et
al
fabmab
conjug
b
cell
lymphoma
israel
et
al
carexpress
vari
cancer
cell
adapt
frequent
mediat
markedli
enhanc
transduct
cancer
cell
yet
anoth
type
antibodybas
adapt
conjug
gener
link
fab
fragment
basic
fibroblast
growth
factor
target
variou
cancer
cell
goldman
et
al
roger
et
al
rancourt
et
al
synthet
lunghom
peptid
trepel
et
al
hcfragment
tetanu
toxin
target
neuron
cell
schneider
et
al
recombin
bispecif
adapt
molecul
possess
attribut
advantag
applic
vector
target
compar
chemic
conjug
foremost
produc
standard
procedur
prokaryot
eukaryot
express
yield
welldefin
molecul
tandem
singl
chain
variabl
fragment
tandem
scfv
see
also
singl
chain
diabodi
scdb
see
also
use
target
ad
gene
transfer
haisma
cowork
demonstr
ad
transduct
glioblastoma
carcinoma
cell
increas
complex
viru
recombin
tandem
scfv
haisma
et
al
group
report
scdb
specif
ad
fiber
endoglin
express
prolif
endothelium
facilit
target
transduct
endotheli
cell
nettelbeck
et
al
contrast
tandem
scfv
express
eukaryot
cell
scdb
produc
bacteria
ad
transduct
also
target
gastric
cancer
cell
tandem
scfv
adapt
bind
epcam
heideman
et
al
dc
tandem
scfv
adapt
brandao
et
al
melanoma
cell
use
scdb
adapt
bind
melanoma
surfac
antigen
hmwmaa
nettelbeck
et
al
breast
cancer
cell
either
tandem
scfv
scdb
bind
cea
korn
et
al
improv
detarget
receptorblind
ad
mutant
combin
tandem
scfv
scdb
adapt
deriv
scfv
retain
bind
mutant
fiber
van
beusechem
et
al
nettelbeck
et
al
carett
et
al
ad
vector
could
bind
car
even
individu
fiber
molecul
protect
complex
adapt
consequ
strategi
combin
geneticimmunolog
tropismmodif
implement
increas
select
gene
transfer
recombin
antibodyderiv
adapt
target
adenovir
transduct
also
obtain
fusion
scfv
ligand
protein
egf
upar
watkin
et
al
harvey
et
al
ligand
peptid
nicklin
et
al
altern
cellbind
scfv
fuse
monomer
trimer
solubl
car
kashentseva
et
al
pereboev
et
al
kim
et
al
sapinoro
et
al
scarderiv
adapt
offer
advantag
improv
affin
fiber
scar
trimer
howev
natur
bind
receptorblind
fibermut
virus
strategi
also
demonstr
adapt
besid
target
gene
transfer
might
also
influenc
outcom
gene
therapi
differ
way
adenovir
gene
transfer
dc
adapt
adapt
result
dc
activ
thu
influenc
type
immun
respons
immun
versu
toler
tillman
et
al
sapinoro
et
al
vitro
studi
adapt
molecul
includ
variou
bispecif
antibodi
clearli
proven
viral
cell
entri
redirect
via
novel
cell
surfac
receptor
thu
reprogram
viru
tropism
demonstr
establish
cell
cultur
freshli
purifi
normal
tumor
cell
tissu
explant
demonstr
dctarget
gene
transfer
skin
explant
de
gruijl
et
al
possibl
applic
bispecif
antibodi
antibodyderiv
gene
transfer
adapt
first
due
modular
composit
opportun
rapidli
comparison
genet
engin
virus
produc
new
adapt
chemic
genet
mean
facilit
analysi
comparison
screen
cell
surfac
molecul
feasibl
target
viral
gene
transfer
second
applic
adapt
ex
vivo
gene
therapi
interest
exampl
genet
vaccin
cancer
infecti
diseas
ex
vivo
gene
transfer
dc
isol
patient
gene
therapi
inherit
diseas
ex
vivo
gene
transfer
hematopoiet
stem
cell
applic
howev
retrovir
vector
prefer
ad
vector
facilit
stabl
gene
transfer
thu
prolong
gene
correct
replac
tabl
note
adaptertarget
retrovir
gene
transfer
demonstr
recent
see
gene
therapi
applic
howev
requir
vivo
gene
transfer
establish
adapt
target
gene
transfer
vivo
extens
studi
stabil
effici
select
adaptervector
complex
vivo
applic
need
wherea
rigor
studi
evalu
pharmacolog
therapeut
paramet
adaptertarget
gene
transfer
still
done
initi
studi
shown
efficaci
adaptertarget
vivo
effort
facilit
gene
therapi
pulmonari
vascular
diseas
reynold
colleagu
investig
fabmab
conjug
adapt
bind
angiotensinconvert
enzym
ace
target
ad
gene
transfer
lung
endothelium
rat
reynold
et
al
system
applic
adapterbound
uncomplex
ad
vector
shown
adapt
increas
gene
transfer
lung
importantli
gene
transfer
direct
endotheli
cell
moreov
gene
transfer
liver
organ
respons
adinduc
side
effect
reduc
henc
studi
demonstr
system
stabil
adaptervector
complex
adapterdepend
vector
de
retarget
vivo
adapt
sever
studi
mice
show
adapterdepend
reduct
liver
transgen
express
system
inject
ad
vector
reduc
toxic
admedi
genet
prodrug
activ
therapi
furthermor
adapt
increas
therapeut
activ
admedi
genet
prodrug
activ
periton
malign
ad
vector
inject
intraperiton
rancourt
et
al
gu
et
al
printz
et
al
vivo
stabil
adaptorvector
complex
also
demonstr
recombin
protein
trimer
monomer
scar
significantli
block
liver
gene
transfer
ad
system
applic
scarad
vector
complex
mice
kim
et
al
howev
differ
studi
scarscfv
adapt
target
cea
also
reduc
liver
transduct
ad
vector
system
inject
adapterviru
complex
mice
li
et
al
system
inject
adapt
also
increas
adenovir
transduct
ceaposit
reduc
transduct
ceaneg
tumor
graft
mous
liver
furthermor
trimer
deriv
scarcea
adapt
mediat
improv
target
adenovir
gene
transfer
vitro
vivo
combin
transcript
target
use
promot
trimer
adapt
increas
therapeut
activ
time
reduc
liver
toxic
genet
prodrug
activ
therapi
hsvtkgcv
li
et
al
studi
scaregf
trimer
confirm
retarget
properti
scarderiv
adapt
vivo
liang
et
al
huang
et
al
addit
facilit
select
gene
transfer
target
adenovir
cell
bind
entri
interest
also
improv
oncolyt
ad
toward
end
adapt
molecul
interest
redirect
inject
viru
target
tumor
also
allow
target
progeni
virus
oncolyt
ad
produc
patient
tumor
gene
encod
recombin
bispecif
adapt
insert
genom
virus
use
tandem
scfv
specif
ad
fiber
egfr
van
beusechem
cowork
demonstr
increas
viral
spread
oncolysi
two
threedimension
tumor
cell
cultur
van
beusechem
et
al
carett
et
al
although
wide
investig
ad
vector
adapt
also
shown
facilit
target
cell
entri
virus
adenoassoci
virus
aav
small
nonenvelop
virus
frequent
use
divers
gene
therapi
applic
bune
et
al
tropismmodif
aav
vector
achiev
bispecif
fabfab
antibodi
conjug
adapt
specif
viru
capsid
integrin
facilit
gene
transfer
megakaryocyt
permiss
unmodifi
aav
vector
bartlett
et
al
nonhuman
coronavirus
envelop
rna
virus
natur
enter
human
cell
infect
human
cancer
cell
establish
bispecif
tandem
scfv
specif
coronaviru
surfac
glycoprotein
egfr
wurding
et
al
b
idea
approach
select
kill
tumor
cell
lytic
viru
infect
rather
viral
gene
transfer
similar
result
obtain
use
recombin
adapt
built
solubl
coronaviru
receptor
fuse
egfrbind
scfv
wurding
et
al
b
newcastl
diseas
viru
develop
viral
oncolysi
gene
therapi
retarget
use
recombin
adapt
built
virusbind
scfv
bian
et
al
retrovirus
envelop
rna
virus
insert
genom
revers
transcript
chromosom
infect
cell
therefor
retrovir
vector
facilit
longterm
gene
transfer
especi
suitabl
gene
correct
therapi
monogenet
diseas
adapt
target
retroviru
cell
entri
report
recombin
protein
built
viru
receptor
extracellular
domain
fuse
egf
vegf
egfrspecif
scfv
snitkovski
young
boerger
et
al
snitkovski
et
al
gene
therapi
exploit
express
antibodi
patient
might
advantag
achiev
sustain
andor
effici
antibodi
concentr
andor
favor
antibodi
biodistribut
local
express
thu
gene
therapi
tool
interest
overcom
rapid
antibodi
clearanc
poor
access
tumor
report
antibodi
inject
protein
genet
antibodi
therapi
implement
vivo
ex
vivo
gene
transfer
fig
ie
direct
inject
gene
transfer
vector
patient
gene
transfer
cultur
previous
isol
cell
follow
inject
result
genet
engin
cell
respect
depend
design
gene
transfer
vector
genet
antibodi
applic
transient
perman
constitut
induc
target
ubiquit
exampl
retrovir
vector
allow
stabl
gene
transfer
induc
promot
facilit
control
antibodi
express
target
vector
direct
gene
transfer
specif
cell
type
see
sect
therefor
gene
therapi
possess
high
potenti
flexibl
implement
improv
antibodi
deliveri
specif
applic
howev
area
research
still
infanc
widespread
investig
warrant
advent
recombin
dna
technolog
becam
possibl
establish
novel
strategi
antibodi
product
engin
antibodi
properti
exampl
affin
matur
human
format
singl
chain
fragment
fusion
protein
immunotoxin
recombin
antibodi
frequent
produc
bacteria
gene
transfer
eukaryot
cell
also
util
vitro
product
immunoglobulin
antibodi
fragment
antibodi
fusion
protein
establish
engin
recombin
gene
construct
eukaryot
antibodi
express
also
vivo
product
antibodi
becam
feasibl
exampl
express
function
recombin
mab
mice
transfer
genet
engin
cell
noel
et
al
vivo
gene
transfer
adenovir
aav
vector
noel
et
al
jiang
et
al
watanab
et
al
lewi
et
al
fang
et
al
skaric
et
al
de
et
al
ho
et
al
toward
end
fang
cowork
optim
antibodi
product
express
heavi
light
chain
mab
equal
amount
singl
open
read
frame
use
ribosom
skip
sequenc
therebi
serum
level
mgml
antibodi
extend
time
period
obtain
mice
inject
singl
dose
aav
vector
subsequ
studi
group
demonstr
use
induc
promot
serum
antibodi
level
vivo
gene
transfer
repeatedli
shut
fang
et
al
repres
promis
strategi
increas
safeti
andor
facilit
dose
adapt
potenti
futur
clinic
applic
genet
antibodi
deliveri
de
cowork
combin
genet
deliveri
mab
gene
aav
ad
vector
achiev
rapid
ad
persist
aav
antibodi
product
de
et
al
function
express
vivo
also
demonstr
recombin
antibodi
fragment
fusion
protein
contain
fragment
adenovir
gene
transfer
whittington
et
al
arafat
et
al
afanasieva
et
al
kasuya
et
al
liu
et
al
express
chimer
antigen
receptor
cell
subsequ
adopt
cell
therapi
anoth
import
applic
genet
antibodi
deliveri
team
develop
genet
deliveri
bispecif
antibodi
engin
cell
report
antitumor
activ
bispecif
diabodi
express
vivo
irradi
genet
engin
cell
blanco
et
al
produc
stabli
transfect
cell
secret
diabodi
specif
cea
second
cell
line
addit
secret
bival
ceaspecif
diabodi
fuse
extracellular
domain
coinject
ceaposit
tumor
cell
mice
genet
engin
cell
show
antitumor
activ
compar
coinject
control
cell
subsequ
proofofprincipl
studi
group
engin
lentivir
gene
transfer
vector
encod
diabodi
compt
et
al
vector
facilit
transduct
differ
type
hematopoiet
cell
show
prolong
secret
activ
diabodi
vitro
antitumor
activ
vivo
followup
studi
group
demonstr
also
implant
lentivir
transduc
endotheli
cell
mice
result
prolong
product
diabodi
therapeut
activ
compt
et
al
studi
aim
therapeut
regimen
allow
product
therapeut
antibodi
neovessel
incorpor
ex
vivo
engin
endotheli
cell
genet
deliveri
bispecif
antibodi
also
report
intracellular
applic
cell
surfac
local
two
membran
protein
could
block
express
correspond
bispecif
tetraval
antibodi
target
endoplasm
reticulum
jendreyko
et
al
intracellular
bispecif
antibodi
show
antiangiogen
activ
vitro
superior
monoval
control
antibodi
similar
construct
specif
mediat
antiangiogen
antitumor
activ
vivo
adenovir
gene
transfer
jendreyko
et
al
proof
principl
demonstr
sever
cell
cultur
studi
anim
model
util
bispecif
antibodi
target
gene
therapi
feasibl
gene
transfer
deliv
recombin
bispecif
antibodi
base
fundament
work
bispecif
antibodi
adapt
gene
transfer
technolog
consid
improv
therapeut
regimen
gene
therapi
antibodi
therapi
respect
cooper
antibodi
engin
gene
therapist
warrant
develop
bispecif
antibodi
gene
transfer
vector
purpos
